Protein disulfide isomerase inhibition synergistically enhances the efficacy of sorafenib for hepatocellular carcinoma
Jae‐Kyung Won, Su Jong Yu, Chae Young Hwang, Sung‐Hwan Cho, Sang‐Min Park, Kwangsoo Kim, Won‐Mook Choi, Hyeki Cho, Eun Ju Cho, Jeong‐Hoon Lee, Kyung Bun Lee, Yoon Jun Kim, Kyung‐Suk Suh, Ja‐June Jang, Chung Yong Kim, Jung‐Hwan Yoon, Kwang‐Hyun Cho – 25 April 2017 – Sorafenib is the only approved targeted drug for hepatocellular carcinoma (HCC), but its effect on patients' survival gain is limited and varies over a wide range depending on pathogenetic conditions.